Dietary Interventions in PsA
Dr. Peter Nash reports on several abstracts at the 2026 EULAR meeting in London, including: OP069; OP070 and POS0050.
Watch video →What's hot!
View all perspectives
What's Hot
Low dose Blinatumomab: Many Relapse with an Unexpected Surprise
Dr. Alfred Kim discusses abstract OP0203 presented at EULAR 2026 in London.
Watch video →
RA BRIDGE and RA BRANCH trials: Baricitinib and VTE Risk
Drs. Mrinalini Dey and Jon Giles discuss abstract LB0009 presented at EULAR 2026 in London
Watch video →
Combination Biologics in PsA: MRI Findings from AFFINITY
Dr. Artie Kavanaugh reports on abstract OP0186 presented at EULAR 2026 in London.
Watch video →
Day 4 Recap: EULAR 2026
Join Drs. Jack Cush, Mrinalini Dey, Antoni Chan, and Yuz Yusof. Abstracts discussed included: LB0001 LB0002 LB0003 LB0005 LB0007 LB0009 RA Plenary POS1350.
Watch video →
EULAR 2026 Recommendations: Immunization
Dr. Jiha Lee reporting from EULAR 2026 in London.
Watch video →
Making Methotrexate More Effective
Dr. Jonathan Kay reports on abstract OP0206 and OP0207 presented at EULAR 2026 in London
Watch video →
Are we failing in the treatment of RA-ILD?
Dr. Janet Pope discusses treatment of RA-ILD after attending the "How to Treat (HOT)" session on RA-ILD at EULAR 2026.
Watch video →
How Many CAR-Ts Do We Need to Test Drive?
Dr. Janet Pope reviews CAR-T therapy at 2026 EULAR 2026, and the issues and questions that remain with its use in rheumatology.
Watch video →
Day 3 Recap: EULAR 2026
Join Drs. Jack Cush, Jiha Lee, Nelly Ziade, and Sheila Reyes for a lively discussion. Abstracts discussed included: OP0348 POS0290 OP0342 POS1068 POS0201 POS0288
Watch video →
New axSpA Criteria: Who gets left out?
Dr. Nelly Ziade discusses abstract OP0236, OP0239, and POS0190 EULAR 2026.
Watch video →
PsA Potpourri: Probiotics & Head-to-Head Data
Dr. Peter Nash reports on abstracts POS0290 and LB0001 at EULAR 2026.
Watch video →
5 years since Patient ID001: Progress on CAR-T Therapy in RMD
Five years on, are we closer to licensing of the first CAR-T therapy in rheumatic and musculoskeletal diseases (RMD)?
Read more →
BMI Outranks Treatment in PsA Outcomes?
Dr. Peter Nash reports on abstract OP0187 presented at EULAR 2026 in London.
Watch video →
BE BOLD: Going Where No PsA Trial Has Gone Before
Dr. Aurelie Najm discusses abstract LB0001 presented at the 2026 EULAR Congress in London
Watch video →
New biomarkers in RA: Who to treat, Who to watch, Who to taper?
Here is my summary of what EULAR 2026 is presenting to us in the field of biomarker-driven personalized care in RA.
Read more →
Debate: Combination Therapies for Inflammatory Arthritis?
Dr. Jonathan Kay reports on the debate, "Combination of targeted therapies in inflammatory arthritis - is the time now?", from EULAR 2026.
Watch video →
sheila RHEUMarampa
1 week 1 day ago
FASTLANE study Ph4 RCT on TOFA+NPX vs. PBO+NPX for early active axSpA TOFA arm significantly achieved inactive dse vs. PBO (p=0.006) at wk 16. Similar results seen in secondary efficacy endpts. Interesting results supporting TOFA use AbsOP0241 @RheumNow #EULAR2026 #EULARBest https://t.co/PQYzE1zm0h
Jiha Lee JihaRheum
1 week 1 day ago
TCZ vs ABA head-to-head in #RA after 1-2 prior b/tsDMARDs: SUNSTAR RCT (n=224) didn't hit its primary endpoint (CDAI change at wk 26, p=0.11). But composite response (treatment persistence + LDA + steroid-sparing) favored TCZ: 50.5% vs 35% (p=0.034). @RheumNow #EULAR2026 OP0205
Jiha Lee JihaRheum
1 week 1 day ago
MTX PO split dose MTX (15mg AM + 10mg PM) vs SC in early seropositive #RA in SCOOT RCT (n=252): SC MTX had better EULAR response at 16 wks (OR 0.55, p=0.049) and ↑ transaminitis with oral split. SC MTX remains the preferred route above 15mg/wk. @RheumNow #EULAR2026 OP0206
Aurelie Najm AurelieRheumo
1 week 1 day ago
RENOIR Ph2b pathogenic T-cell depletion rosnilimab RA
-Primary endpoint DAS28-CRP change wk12
-2.06 to -2.12 (all doses) vs -1.69 PBO p<0.01
-ACR20/50/70 + CDAI LDA all improved vs PBO
-hsCRP reduction across all dose arms
-69% CDAI LDA by wk14
-wk 28 extension shows https://t.co/AMfmSded0D
Aurelie Najm AurelieRheumo
1 week 1 day ago
A new MoA that does not meet it's primary endpoint in RA
SPECIFI-RA Ph2b oral TNFR1 signal inhibitor balinatunfib
ACR20 wk12 NOT significantly diff vs PBO
~48.5–61.8% across doses vs 52.3% PBO
Secondary BALI 200 mg QD:
ACR50: 36.9% vs 18.5% (nominal p=0.0179)
Mechanistic https://t.co/hmZ93JisiO
Mrinalini Dey DrMiniDey
1 week 1 day ago
#OP0225 at #EULAR2026: In this nationwide French cohort, patients with IMIDs had nearly 2x risk of HPV-related cancers or severe dysplasia versus matched controls. Risk was particularly increased in SLE, reinforcing the importance of HPV vaccination and screening. @RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof
1 week 1 day ago
#EULAR2026 OP0228 Is there “something in the air?” Data from US Market Scan: poor quality index was associated with increased risk of #SLE. Although causal inference cannot be deduced, seems an important environmental factor. To check air quality assoc with UV index @RheumNow https://t.co/1FOw7RDA9a
Md Yuzaiful Md Yusof Yuz6Yusof
1 week 1 day ago
#EULAR2026 OP0166 In a phase III RCT in dermatomyositis, brepocitinib, first in class selective SyK-i and JAK1-i showed rapid meaningful improvement in cutaneous DM as early as Week 4 vs PBO. Exciting option and is under FDA Priority Review for approval @RheumNow #EULARBest https://t.co/9b0WurgBkN
Janet Pope Janetbirdope
1 week 1 day ago
Which ‘CAR’ to drive in #SLE?
Comparison of #CD19 #CAR-T
#allogenic vs #Autologous
➡️ comparing #molecular #responses from 2 #lupus studies N=12
Both improved cytokine signatures
For
#IFN & #neutrophils
Results similar not identical
?either
#POS0678 #EULAR2026 @RheumNow https://t.co/Lcpv3qJ6tU
Mrinalini Dey DrMiniDey
1 week 1 day ago
#OP0224 at #EULAR2026: Poor air quality may contribute to lupus risk. In a cohort of 8.3 million people, higher AQI exposure and more unhealthy air quality days were associated with increased incident SLE. Adds to evidence linking environmental exposures & autoimmunity. @RheumNow
Jiha Lee JihaRheum
1 week 1 day ago
JAKi vs TNFi in #RA: Swedish registry (n=21,314) shows JAKi carries ↑ risk of hospitalized infections (IRR 1.23) and ~2x viral infection risk after accounting for treatment discontinuation. Treatment selection matters. @RheumNow #EULAR2026 POS0070
Aurelie Najm AurelieRheumo
1 week 1 day ago
Do we really need yet another JAKi?
COURAGE-RA RCT phIII JAK1-selective Zemprocitinib RA bDMARDs IR
Primary endpoint ACR20 at wk24
79.1% vs 39.7% PBO (p<0.0001)
wk24 ACR50: 55.8% vs 22.0%
wk 24 DAS28-CRP ≤3.2: 67.0% vs 23.4%
No new safety signal
Looks very similar to other https://t.co/b0RMBWl4Xx
Aurelie Najm AurelieRheumo
1 week 1 day ago
Low-dose blinatumomab in multidrug-resistant RA
15 pts 96h cycles CD3×CD19 T-cell engager
DAS28-CRP: 4.8 → 2.4
3 mo ACR20 100% ACR50 73% ACR70 53%
DAS28 remission 33%
But... only transient efficacy with
93% relapse after stopping treatment
Authors highlight response to https://t.co/GCS6774tJt
Md Yuzaiful Md Yusof Yuz6Yusof
1 week 1 day ago
#EULAR2026 OP0221 Can we refine response measure in #lupusnephritis RCT? Asia Pacific cohort: construct validity of TRM-SLE definition: 1)RCT entry threshold uPCR >1g/g; 2)clinically meaningful response >50% improvement in UPCR; 3)stricter complete response UPCR<0.2g/g @RheumNow https://t.co/dlErgyFMZP
Mrinalini Dey DrMiniDey
1 week 1 day ago
#OP0223 at #EULAR2026: Not every lupus nephritis patient may need upfront triple therapy. Using EULAR 2025 prognostic factors, triple therapy significantly improved complete renal response only in high-risk patients, supporting more precision-based treatment approach. @RheumNow https://t.co/F8Kn23YjNr
